Paramjit Kaur

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino et al. · Journal of Clinical Oncology · 2018 · 499 citations · Full text

Neuro-oncology, Stable Cns Metastases, Cns Orr +15

Early expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes

Liping Yu, David T. Robles, Norio Abiru et al. · Proceedings of the National Academy of Sciences · 2000 · 452 citations · Full text

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe et al. · Journal of Clinical Oncology · 2013 · 157 citations · Full text

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

Lecia V. Sequist, Jean‐Charles Soria, Shirish M. Gadgeel et al. · Journal of Clinical Oncology · 2014 · 143 citations

Pathology, Pharmacotherapy, T790m Mutation +21

Difluprednate 0.05% Versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: A Phase III, Multicenter, Randomized Study

John D. Sheppard, Melissa Toyos, John H. Kempen et al. · Investigative Ophthalmology & Visual Science · 2014 · 85 citations · Full text